Till startsida
University of Gothenburg
To content Read more about how we use cookies on gu.se

Members / partners of PREVENT-ROP

  1. University of Gothenburg (SE)
  2. PREMAcure AB (SE)
  3. Mediagnost (DE)
  4. Smerud AB (NO)
  5. Boston Children's Hospital (USA)
  6. Lund University (SE)
  7. Karolinska Institutet (SE)
  8. Instituto Giannina Gasi (IT)
  9. University of Amsterdam (NL)
  10. University of Cambridge (UK)


University of Gothenburg logo

University of Gothenburg, Sahlgrenska Academy (UGOT)


General description

UGOT is a non-profit, public body for higher education. It has approximately 50,000 students (25,000 full-time students) and 5,000 employees. With its eight faculties, UGOT is also the most wide-ranging and versatile university in Sweden. The quality of UGOT has earned recognition in the form of numerous awards, including a recent Nobel Prize.

All faculties at UGOT are involved in EU-projects and about 110 projects in FP6 are running and approx. 100 projects in the FP7 have started. These projects are managed by Research and Innovation Services providing FP7 project support.


Ann Hellström, Professor
Chatarina Löfqvist, Associate professor
Aimon Niklasson, MD PhD
Anna-Lena Hård, MD PhD

Ann Hellström, Professor, University of GothenburgChatarina Löfqvist, Associate professor, University of Gothenburg









PREMAcure AB logo



General description

PREMA is a linked, upstream SME devoted to development of pharmaceutical interventions to prevent complications of preterm birth.

PREMA coordinated and cosponsored the accomplished phase-I trial and is currently cosponsoring and coordinating the on-going phase-II trial.

PREMA owns, or has licensed in, and manages all patent rights related to “prediction and prevention of complications of preterm birth” and is also the legal body for agreements with suppliers of services (e.g. monitoring of clinical trials), purchase of materials (e.g. study drug substance) and manufacturing (study drug product). 

PREMA has obtained SME status with EMA (EMA/SME/315/11) and has the status with MPA in Sweden as official sponsor of the on-going phase-II trial.


Jan Borg, CEO
Daniel E. Walker, PhD

Jan Borg, CEO, PREMAcure AB









Mediagnost logo

Mediagnost (MEDI)


General description

MEDI, a SME, was founded in 1985 and is dedicated to research, development, manufacture and distribution of In-vitro-diagnostic test systems and raw materials. The company is privately held and has 20 employees.

MEDI operates in several medical and scientific fields. Main focus up to now has been endocrinology and infectious diseases. The affiliation of the company to the university of Tuebingen and to other national as well as ones led to participation in several research projects, granted by e.g. BMBF (Ministry of Science) and BMWi (Ministry of Technology).

MEDI offers special products for differential growth diagnostics, for adipokine research, for certain CNS diseases and for determination of Hepatitis A Virus (Infection and the Virus itself).


Angelika Haage, PhD
Markus Langkamp, PhD
Lutz Prizdun, PhD

Team Mediagnost









Smerud logo

Smerud Medical Research (SMER)


General description

SMER is a clinical Contract Research Organization operating mainly in the European area with offices in Norway, Denmark, Finland, Sweden, Austria, Hungary, Poland, Russia and the United Kingdom. New offices will be opened in Germany and the US within short. The activities are primarily focused on clinical research management in general, including but not limited to clinical project planning, management and monitoring of phase II-III studies, regulatory affairs, data management, medical writing and general planning, execution, analysis and interpretation of data in all phases of drug development. SMER employs about 75 persons, of whom 60 are clinical research professionals.

SMER is ideally sized and experienced to be a preferred partner for biotech companies in terms of managing clinical trials in a cost-effective setting. The core competence is strategic drug development planning, and despite being a relatively small CRO, the company has developed a strong full-service operational organization. Thus, SMER is able to oversee and undertake clinical proof-of-concept trials (phase IIa) up to and including pivotal phase III trials, and subsequently prepare and execute application for marketing authorization. Operating since 1993, SMERUD has been involved in more than 800 clinical trials.


Kristin A. Bakke, MD
Nadeem Ahmed, PhD
Nils Meland, Statistician
Marie Hutchison, Director Biometrics
Giles Harding, BSc
Knut Smerud, CEO

Knut Smerud, CEO, Smerud









Children’s Hospital Boston and Harvard Medical school’s logo

Boston Children's Hospital (BCH)


General description

Harvard Medical School: A non-profit body for higher education; Full-time faculty 8,924; Nobel Prizes 15 recipients; Howard Hughes Medical Institute investigators 30; Members Institute of Medicine 115; National Academy of Sciences 62; Total MD students 709; Total PhD students 582; MD-PhD Basic sciences 150; Trainees (residents and postdocs) 9,376; 50 clinical depts. with basic and clinical research.

(CHB) Boston Children’s Hospital. A 397 bed non-profit hospital affiliated with Harvard Medical School with many medical advances, from the first successful remission of leukemia in 1947 to a recent successful correction of a heart defect in a fetus. CHB is New England's regional referral paediatric center. CHB trains more paediatricians and has the largest research program with the most NIH research funding of any paediatric hospital worldwide with 1100 scientists in 130 laboratories. All projects are managed by the CHB Research Administration.


Lois Smith, Professor
Theresa Mansfield, Clinical Study Nurse Coordinator
Jing Chen, PhD
Linda Van Marter, MD 

Lois Smith, Professor, Children’s Hospital Boston









Lund University logo

Lund University, Department of Neonatalogy (ULUND)


General description

Lund University is the largest institution of research and higher education in Scandinavia. It was founded in 1666 and today the university has eight faculties; engineering; science; law; social sciences; economics; medicine; humanities & theology; performing arts and several research centres and specialised schools. It is a research intensive university with over 2300 active researchers. The University has a significant experience from EU Research and has participated in over 650 projects from framework programme 4 and onwards, mainly in the areas of Medicine, Science and Technology. 

The Department of Neonatology in Lund has a long-standing record of clinical and pre-clinical research focused on injurious and protective mechanisms involved in brain injury following preterm birth. The research platform encompasses extensive facilities for functional and morphological neuro-imaging during and following intensive care and for longitudinal neuro-developmental and cardio-vascular evaluation. Research questions are translated from clinical study and evaluated in appropriate experimental in vitro and in vivo models with laboratory facilities for animal housing, tissue culture, molecular biology and protein chemistry.


David Ley, Professor
Ingrid Hansen-Pupp, MD PhD

Team Lund University









Karolinska Institutet logo

Karolinska Institutet (KI)


General description

Karolinska Institutet (KI), founded in 1810, is Sweden’s only university especially focusing on biomedical sciences. In addition, KI annually awards the Nobel Prize in Physiology or Medicine. KI ranks as one of the world’s leading medical universities, thanks in part to the quality of its research activities, which today account for 40 per cent of all medical research in Sweden. Research at KI has a strong European dimension, with almost 200 FP6 projects and 230 FP7 projects including 28 as coordinator.

The department of neonatology at KI is the largest tertiary care NICU in Sweden. The department is responsible for neonatal intensive care for the greater Stockholm region with a total annual birth rate of 30,000 infants/year, and is responsible for NICUs at three of the Stockholm hospitals.

Neonatal neurology is a main research area in the department. Research includes experimental studies on brain development, respiratory control and brain damages, clinical trials on both normal brain development, emergence of consciousness, pain and perinatal brain damages.


Boubou Hallberg, MD PhD
Dirk Wackernagel, MD PhD
Camilla Halzius

Boubou Hallberg, MD PhD, Karolinska InstitutetDirk Wackernagel, MD PhD, Karolinska InstitutetCamilla Halzius, Karolinska Institutet









Instituto Giannina Gaslini logo

Instituto Giannina Gaslini (Gaslini Children’s Hospital) (IGG)


General description

IGG is one of the most important paediatric hospital in Italy. All paediatric fields, including ophthalmology, support Neonatal Intensive Care Unit in caring preterm infants. IGG is the most important national paediatric research center, with 14 top Italian scientists (H-index > 30)

In our Neonatal Intensive Care Unit (NICU) more than 100 Very Low Birth Weight Infants (VLBWI) are admitted every year.


Luca Antonio Ramenghi, MD PhD
Paolo Capris, Professor
Enrico Priolo, MD
Riccardo De Marco, MD
Andrea Rossi, MD PhD

University of Amsterdam logo

University of Amsterdam (UAMS)


General description

UAMS is a non-profit, public body for higher education. It has approximately 32,000 students and 6,000 employees. At the University around 400 students receive their PhD degree annually and over 8000 articles are published in peer reviewed journals.

At UAMS around 260 students receive their PhD degree annually and over 6,500 articles are published in peer reviewed journals.


Hans van Goudoever, Professor
Anton van Kaam, MD PhD
Mirjam van Weissenbruch, MD PhD

Hans van Goudoever, Professor, University of AmsterdamAnton van Kaam, MD PhD, University of AmsterdamMirjam van Weissenbruch, MD PhD, University of Amsterdam









University of Cambridge logo

University of Cambridge (UCAM)

United Kingdom

General description

UCAM is a non-profit, public body for higher education and research. UCAM is a world-leading university based in Cambridge, UK. Founded in 1209, UCAM is consistently ranked in the world's top five universities for teaching and research. The Department of Paediatrics forms part of the School of Clinical Medicine and comprises two Professors of Paediatrics, two Senior Lecturers and many Clinical Lecturers, Clinical Research Fellows, research nurses and non-clinical and support staff. The Department also hosts the Cambridge Paediatric Diabetes and Endocrinology Clinical Trials Unit who have experience in all aspects of study design, set-up, management and monitoring.

The Department has been involved in several multicenter paediatric/neonatal clinical trials. It was the coordinating centre and lead for the NIRTURE trial of insulin therapy in premature neonates (Professor David Dunger CI). It has previously recruited babies to other neonatal trials both industry Sponsored and Academic studies, including: PROGRAMMES, INIS, ADEPT, BOOSTII and MABN007.The Department has also been a participating centre in many other clinical trials in older children.


David Dunger, Professor
Kathryn Beardsall, MD

David Dunger, Professor, University of Cambridge

Kathryn Beardsall, MD, University of Cambridge

Funded by

 Funded by Seventh framework programme

Contact Information

Chatarina Löfqvist, Project Manager

Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, The Queen Silvia Children's Hospital, SE-416 85 Gothenburg, SWEDEN

+46 76 867 2719

+46 31 84 89 52

Page Manager: Carola Pfeiffer Mosesson|Last update: 6/22/2016

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?

Denna text är utskriven från följande webbsida:
Utskriftsdatum: 2017-12-14